{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Pregnancy&page=70", "query": { "condition": "Normal Pregnancy", "page": 70 }, "page_size": 10 }, "pagination": { "page": 70, "page_size": 10, "total_count": 1974, "total_pages": 198, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Pregnancy&page=71&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Pregnancy&page=69&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T19:44:13.049Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06168825", "title": "Mind Over Matter for Black and African American Women: A Single Arm Trial Examining Feasibility and Acceptability of a Supportive Intervention", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer", "Breast Cancer", "Brain Cancer", "Central Nervous System Cancer", "Colorectal Cancer", "Esophageal Cancer", "Gynecologic Cancer", "Head and Neck Cancer", "Gastrointestinal Cancer", "Genitourinary Cancer", "Melanoma", "Blood Cancer", "Lung Cancer", "Acceptance and Commitment Therapy", "Mind-Body Therapies", "Psychosocial Intervention" ], "interventions": [ { "name": "Mind Over Matter (MOM)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Inova Health Care Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 40, "start_date": "2024-01-17", "completion_date": "2024-06-04", "has_results": false, "last_update_posted_date": "2025-02-27", "last_synced_at": "2026-11-06T19:44:13.049Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Fairfax, Virginia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06168825" }, { "nct_id": "NCT00003887", "title": "Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Gestational Trophoblastic Tumor", "Kidney Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Neuroblastoma", "Ovarian Cancer", "Sarcoma", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "peripheral blood lymphocyte therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "70 Years", "sex": "ALL", "summary": "1 Year to 70 Years" }, "enrollment_count": null, "start_date": "1998-08", "completion_date": "2003-02", "has_results": false, "last_update_posted_date": "2011-11-30", "last_synced_at": "2026-11-06T19:44:13.049Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003887" }, { "nct_id": "NCT04668521", "title": "Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adnexal Mass", "Germline BRCA1 Gene Mutation", "Germline BRCA2 Gene Mutation", "Hereditary Breast and Ovarian Cancer" ], "interventions": [ { "name": "OVA360", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Aspira Women's Health", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 215, "start_date": "2020-05-04", "completion_date": "2023-12-15", "has_results": false, "last_update_posted_date": "2023-12-26", "last_synced_at": "2026-11-06T19:44:13.049Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04668521" }, { "nct_id": "NCT02897765", "title": "A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urinary Bladder Cancer", "Bladder Tumors", "Transitional Cell Carcinoma of the Bladder", "Malignant Melanoma", "Melanoma", "Skin Cancer", "Carcinoma, Non-Small-Cell Lung", "Lung Cancer" ], "interventions": [ { "name": "NEO-PV-01", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Adjuvant", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "BioNTech US Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2016-10", "completion_date": "2020-05", "has_results": false, "last_update_posted_date": "2021-02-25", "last_synced_at": "2026-11-06T19:44:13.049Z", "location_count": 9, "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02897765" }, { "nct_id": "NCT06239272", "title": "NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adipocytic Neoplasm", "Liposarcoma", "Atypical Fibroxanthoma", "Angiomatoid Fibrous Histiocytoma", "Fibrosarcoma NOS", "Myxofibrosarcoma", "Angiosarcoma", "Osteosarcoma, Extraskeletal", "Dedifferentiated Liposarcoma", "Myxoid Liposarcoma", "Pleomorphic Liposarcoma", "Myxoid Pleomorphic Liposarcoma", "Low Grade Fibromyxoid Sarcoma", "Sclerosing Epithelioid Fibrosarcoma", "Malignant Tenosynovial Giant Cell Tumor of Soft Tissue", "Epithelioid Hemangioendothelioma", "Glomus Tumor", "Inflammatory Leiomyosarcoma", "Leiomyosarcoma", "Ossifying Fibromyxoid Tumor, Malignant", "Myoepithelioma", "Synovial Sarcoma", "Epithelioid Sarcoma", "Perineurioma, Malignant", "Clear Cell Sarcoma", "Extraskeletal Myxoid Chondrosarcoma", "Granular Cell Tumor, Malignant", "Melanotic Malignant Nerve Sheath Tumor", "Malignant Peripheral Nerve Sheath Tumor", "Perivascular Epithelioid Tumor, Malignant", "Intimal Sarcoma", "Myoepithelial Carcinoma", "Undifferentiated Sarcoma", "Pleomorphic Sarcoma, Undifferentiated", "Round Cell Sarcoma, Undifferentiated", "NTRK-Rearranged Spindle Cell Neoplasm", "Phosphaturic Mesenchymal Tumor, Malignant", "Round Cell Sarcoma", "Well Differentiated Liposarcoma", "Giant Cell Tumor of Soft Parts NOS", "Low Grade Myofibroblastic Sarcoma", "Dermatofibrosarcoma Protuberans, Fibrosarcomatous" ], "interventions": [ { "name": "Surgical resection", "type": "PROCEDURE" }, { "name": "Proton beam radiation therapy", "type": "RADIATION" }, { "name": "Pazopanib", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 139, "start_date": "2024-03-27", "completion_date": "2037-06", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-11-06T19:44:13.049Z", "location_count": 7, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Baton Rouge, Louisiana + 4 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06239272" }, { "nct_id": "NCT04272034", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "MSI-H/dMMR Tumors", "Cutaneous Squamous Cell Carcinoma", "Urothelial Carcinoma, HCC", "Cervical Cancer", "Esophageal Squamous Cell Carcinoma", "Merkel Cell Carcinoma", "Small-cell Lung Cancer", "Mesothelioma", "PD-L1 Amplified Tumor (9p24.1)", "Nasopharyngeal Carcinoma", "Cyclin-dependent Kinase 12 Mutated Tumors", "Basal Cell Carcinoma (Unresectable or Metastatic)", "Sarcomatoid Renal Cell Carcinoma", "Clear Cell Ovarian or Endometrial Carcinoma", "Anal Carcinoma", "Squamous Cell Penile Carcinoma", "DNA Polymerase Epsilon Mutated Tumors (P286R and V411L)" ], "interventions": [ { "name": "INCB099318", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2021-03-26", "completion_date": "2024-08-16", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-11-06T19:44:13.049Z", "location_count": 3, "location_summary": "Hackensack, New Jersey • Greenville, South Carolina • Nashville, Tennessee", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "Greenville", "state": "South Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04272034" }, { "nct_id": "NCT07523581", "title": "EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alport Syndrome, X-Linked", "Alport Syndrome, Autosomal Recessive" ], "interventions": [ { "name": "Exaluren", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eloxx Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 24, "start_date": "2026-06-30", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-11-06T19:44:13.049Z", "location_count": 7, "location_summary": "Los Angeles, California • Stanford, California • Denver, Colorado + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07523581" }, { "nct_id": "NCT02775500", "title": "Apremilast Pregnancy Exposure Registry", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Psoriatic Arthritis", "Psoriasis" ], "interventions": [ { "name": "apremilast", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 233, "start_date": "2014-11", "completion_date": "2025-07", "has_results": false, "last_update_posted_date": "2025-01-28", "last_synced_at": "2026-11-06T19:44:13.049Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02775500" }, { "nct_id": "NCT00035334", "title": "Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Secondary (AA) Amyloidosis", "Rheumatoid Arthritis", "Nephrotic Syndrome", "Familial Mediterranean Syndrome", "Kidney Diseases", "Gastrointestinal Diseases" ], "interventions": [ { "name": "NC-503 (Anti-amyloidotic (AA) Agent)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bellus Health Inc. - a GSK company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2001-10", "completion_date": "2004-12", "has_results": false, "last_update_posted_date": "2006-02-14", "last_synced_at": "2026-11-06T19:44:13.049Z", "location_count": 4, "location_summary": "Indianapolis, Indiana • Boston, Massachusetts • Rochester, Minnesota + 1 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00035334" }, { "nct_id": "NCT00689065", "title": "Safety Study of CALAA-01 to Treat Solid Tumor Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Solid Tumor" ], "interventions": [ { "name": "CALAA-01", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calando Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2008-05", "completion_date": "2012-09", "has_results": false, "last_update_posted_date": "2013-11-01", "last_synced_at": "2026-11-06T19:44:13.049Z", "location_count": 3, "location_summary": "Duarte, California • Los Angeles, California • San Antonio, Texas", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00689065" } ] }